Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

類似資料

• Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo
  著者:: Lopez, Salvatore, 等
  出版事項: (2015)
• Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo
  著者:: Menderes, Gulden, 等
  出版事項: (2017)
• Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro
  著者:: Zhu, Liancheng, 等
  出版事項: (2015)
• Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
  著者:: Ferrari, Francesca, 等
  出版事項: (2015)
• PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
  著者:: Black, Jonathan D, 等
  出版事項: (2015)